Business Context and Reporting Period
Company: Achieve Life Sciences, Inc. (ACHV)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2023
Reporting Period: Second Quarter of 2023
This filing serves as a notification that the company issued a press release on August 14, 2023, announcing its financial results for the second quarter of 2023. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Source data does not provide clear values for financial metrics in this specific document.
Material Changes
No material changes or comparative financial data are detailed in the text of this Form 8-K. The filing solely references the issuance of the Q2 2023 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2023 revenue, net loss, and cash position figures.
- Verify the company's liquidity status and runway based on the cash flow details in the press release.
- Check for any updated operational milestones or product development timelines mentioned in the full press release.
- Confirm the trading status of Common Stock (ACHV) on the Nasdaq Capital Market.